Last reviewed · How we verify
NCT07536061
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
Phase 1 trial testing SRP-1005 in Huntington's Disease in 32 participants. Not yet recruiting.
30 November 2027
Quick facts
| Lead sponsor | Sarepta Therapeutics, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 32 |
| Start date | 5 May 2026 |
| Primary completion | 30 November 2027 |
| Estimated completion | 30 November 2027 |
| Sites | 2 locations across New Zealand |
Drugs / interventions tested
- SRP-1005
- Placebo
Conditions studied
- Huntington's Disease — all drugs for Huntington's Disease →
Sponsor
Sarepta Therapeutics, Inc. — full company profile →
Who can join
Adults 21 to 70, any sex, with Huntington's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07536061
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Huntington's Disease
Currently open trials in the same condition.
- NCT07246941 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease · Phase 1 · recruiting
- NCT06585449 — A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease · Phase 1 · recruiting
- NCT02855476 — HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's · recruiting
Other Sarepta Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT07542314 — Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a · Phase 4 · not yet recruiting
- NCT06952686 — A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants · Phase 3 · withdrawn
- NCT06747273 — Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Mu · Phase 1 · terminated
- NCT06597656 — A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therape · Phase 1 · terminated
- NCT06270719 — An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscul · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07536061 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sarepta Therapeutics, Inc.
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07536061.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing